Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wir
DAK-Gesundheit awarded a contract of undisclosed value to betapharm Arzneimittel GmbH for Healthcare & Medical in January 2026 — one of 389 awards this buyer has made.
Buying agency
DAK-GesundheitWinning supplier
betapharm Arzneimittel GmbHContract description
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Teriflunomid, ATC L04AK02 für die Zeit 01.10.2025 - 31.12.2025 (zzgl. Verlängerungsoption 1x12 Monate)
Related awards · DAK-Gesundheit
389 awardsThe buyer's full award list ranked by value, with the winning supplier, date and sector on every row — plus CSV / API export.
- ocds-ted-210283-2024Aktivital GmbH€9.1M10 Apr 2024 Healthcare
- ocds-ted-211590-2024Kraaibeek GmbH€2.5M10 Apr 2024 Healthcare
- ocds-ted-828775-2025news aktuell GmbH€38.0K12 Dec 2025 IT
Other wins · betapharm Arzneimittel GmbH
7 winsThe supplier's complete win history across every buyer it sells to — not just the handful shown here.
- ocds-ted-104419-2026-7GWQ ServicePlus AGNot disclosed13 Feb 2026 Healthcare
- ocds-ted-20212-2026-3DAK-GesundheitNot disclosed13 Jan 2026 Healthcare
- ocds-ted-281786-2026-1DAK-GesundheitNot disclosed24 Apr 2026 Healthcare
Premium · full dataset
See the full award context.
Competing bids, award margins and every related contract for DAK-Gesundheit and betapharm Arzneimittel GmbH — one subscription unlocks everything.
Sign Up Free →Free account · cancel anytime · 14-day money-back